Vicore Pharma Holding AB (publ)
The answer first
Does Vicore Pharma Holding beat the market?
No, Vicore Pharma Holding has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 16% of Nordic stocks
- Quality60
- Value3
- Trend32
No. 146 of 195 in healthcare
Max for seven days
Follow Vicore Pharma Holding with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Vicore Pharma Holding
Your first answer is free, no account needed.
Do you own Vicore Pharma Holding, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Vicore Pharma Holding and a few more. Free, no card.
Super Stock+46.3%In short
- Vicore Pharma Holding has risen 1.2% over the past year, including dividends.
- Overall, Vicore Pharma Holding ranks better than 16% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 82.4%. The price is 71.9% below its peak now.
What do analysts think of Vicore Pharma Holding?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 16% of Nordic stocks.
No. 146 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 108 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−70.7%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 174 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity3.9
- P/SPrice divided by sales742.3
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 104 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−6.5%
- 6 months−16.7%
- 9 months−4.3%
- 12 months+1.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Vicore Pharma Holding
10 funds we follow own Vicore Pharma Holding. The share is how much of the fund the stock makes up.
- Norway1
- Sweden9
- PLUS Hälsovård Sverige IndexSweden · PLUS1.0%
- Atlant OpportunitySweden · Atlant0.2%
- Skandia Småbolag Sverige Exponering ASweden · Skandia0.1%
- PLUS Småbolag Sverige IndexSweden · PLUS0.1%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.1%
- PLUS Mikrobolag Sverige IndexSweden · PLUS0.1%
- PLUS Allabolag Sverige IndexSweden · PLUS0.0%
- Skandia Sverige ExponeringSweden · Skandia0.0%
From the funds' latest known holdings.
About Vicore Pharma Holding
Vicore Pharma Holding AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 50 employees.
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.


See the full analysis of Vicore Pharma Holding.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card